

We are seriously interested in your device. The device can use two-step feature of the device are described in the brief

I write now because we are interested in your device, if we were to produce it, we would be very grateful if you could be able to speak briefly with me and my colleagues about these open questions. I would be very interested to meet you in person, if you are available, to discuss the control for this epidemic. Your input would be invaluable as we weigh the risks and benefits of pivoting the cost to this application.

With
gary

Gary Schoolnik, M.D.
Professor of Medicine
Stanford Medical School
Attending Physician (Internal Medicine)
Chief Medical officer
Visby Medical

Linda P. Fried
Jean and Dela Garza Professor of
Professor of Epidemiology
Mailman School of Public Health
Professor of Medicine, Vagelos College of Physicians and Surgeons
Senior Lecturer
Columbia University

Hi, Patty -

Exec. speak at a [Upcoming Coronavirus Preparedness Conference](#) in Washington, D.C. The conference is a [free event](#) being organized by Synapse [Public Health](#).

Given the nature of [this event](#), invitation and refer to CDC?

Thanks for your input.

5. If someone other than the self-isolating (name):

Thank you for contributing solutions to this health crisis.

With best regards,
Linda

Linda P. Fried, M.D., M.P.H.
Deputy Director of Public Health
Professor of Epidemiology
Mailman School of Public Health
Professor of Medicine
Senior Vice President for Irving I. Medical Center
Columbia University

- Anne Schuchat will give a brief explanation of our understanding of the virus and development of countermeasures.
- Acting Chief of Staff Mick Mulvaney will open the floor for questions and moderate the proceedings, as possible, that White House stand in here (Eric Upton and or Mike McKenna).

Expected

Members (Confirmed RSVPs thus far)

- Senator James Risch
- Leader McCarthy
- Rep. Kay Granger
- Rep. Greg Walden
- Rep. Nita Lowey

Briefers

- DHS – Alex Zemske
- CDC – Dr. Anne Schuchat
- NIAID – Dr. Anthony Fauci
- ASPR – Dr. Bob Radtke
- FDA – Dr. Steve Hahn
- DEIS – Ken Chen
- NSC – Anthony...
- NSC – Matt...
- State – Stephen Birnbaum
- DOE – ...

NIH-001935

Danfart Ager

1:30-2:00 pm – Opening Remarks

Dr. Anthony Fauci, Director

International Center for Global Health Policy Center

2:00-2:50 pm – Panel Discussion

[The economics, business, and technology] Morgan Kousser

[The economics, business, and technology] Studies (CSIS)

[The foreign politics] Melanie Hart, Center for American Progress (*to be invited*), or Bonnie

Graser, CSIS China Power Project

[The pub

Moderator

2:50-3:30 pm – Newsmaker Speech

Matt Pottinger, NSC (*to be invited*), CSIS

Moderator and Follow-up CSIS China Power Project

J. Stephen Morrison

Senior Vice President & Director, Global Health

Center for Strategic Studies (CSIS)

1616 Rhode Island Avenue, N.W.

Washington D.C. 20036

(202) 775-0800

but not in Vancouver--the P
one pretty quickly.

To me, one important aspect is the control of respiratory transmission in the hospital. No extensive nebulization/aerosolization, all negative pressure rooms, as for TB treatment.

(Treating patients with respiratory medications)

In the community, standard public health quarantine, contact tracing should be sufficient for starters.

As the number of infections is likely much higher. The 41 deaths are the tip of the iceberg of not 800 infections (5% fatality rate). Although that fatality rate is higher if the mutating virus becomes very contagious—then the impact could be even greater. Containment is so important.

When a new pathogen arrives, children often have mild disease but they are important vectors for transmission in the community. Teaching hygiene and hand washing is important. This is especially true for 2019-nCoV. It is in the air, but it may not be there for a long time point comes.

Happy to help, any way that I can. Thank you for all you and NIAID are doing!!!

Best wishes , Marty

« ...the reduction in H^+ even without the H^+ /K $^+$ -ATPase exposure to esomeprazole acidified the cytosol and esomeprazole in an independent manner hit chronic exposure, which importantly did not have any deleterious effect on epithelial integrity, was linked to decreased ATP4A mRNA levels. These results open up a new therapeutic approach for treating CF lung disease... » (15)

« ...with respect to the gastric H^+ /K $^+$ -ATPase, ATP4A mRNA, which translates to around 65% identity in the protein products... » (15)

« Proton pump inhibitor therapy predisposes to increased risk of developing pneumonia » (16)

« Na $^+$ /H $^+$ Exchangers Are Required for the Development and Function of Vertebrate Vitelline Yolk » (17)

« ATP4a is required for the development of the stomach » (18)

Regarding coronaviruses and Golgi complex:

« ...Coronaviruses assemble in the endoplasmic reticulum (ER) compartment, which is called the ER-Golgi intermediate compartment (ERGIC). The three main envelope proteins (S, M and E) are synthesized in the ER and move through the ERGIC. Golgi retroviral proteins are responsible for virus budding and release with the viral nucleocapsid (...). Once virions have budded into the lumen of the ERGIC, the ~120 nm particles must move through the host secretory pathway to be released from infected cells. Coronaviruses are believed to follow the constitutive secretory pathway through endocytosis. In recent years, a few studies have addressed the release of coronaviruses during infection, a process that involves a complex interplay of host and viral factors... » (19)

« ...Weak bases (which disrupt acidification) and v-ATPase inhibitors block the progression of a pH-activated virus. All block a number of membrane proteins involved in the trafficking of v-ATPase. The v-ATPase is a multi-subunit machinery that involves a subunit of the membrane sector of the v-ATPase, which has been shown to act in endosomes. This subunit undergoes a conformational change, the typical pH drop, which activates the v-ATPase machinery leading to subsequent vesicle formation... » (19)

« ...Pharmacological and other manipulations of the Golgi complex have all been shown to cause slow trafficking of cargo through the Golgi complex and a reduction in Golgi morphology... » (20)

« ...Similar to M2, the infectious bronchitis virus (IBV) coronavirus E protein blocks multiple secretory pathways and is overexpressed in mammalian cells... » (21)

« ...The envelope protein E plays a major role in virus assembly (...). Using coronavirus infectious clones, it was shown that the transmissible gastroenteritis virus E protein is essential for virus production, and murine hepatitis virus lacking E protein is non-infectious. « ...The exact mechanism of coronavirus release after budding into the ERGIC compartment is not known. It is believed that the virus particles exit the ERGIC through the secretory pathway route to the plasma membrane... » (22)

« ...It might be worth investigating whether inhibition of v-ATPase activity or through P1 is with host proteins of the secretory pathway... » (22)

« ...Also important for transportation of newly synthesized acid hydrolases from Golgi to lysosomes » (24)

- «...cardiotonic steroids ouabain inhibited infection of cells by MHV-1 but not IA-24, when the compounds were present during entry of MHV at an early stage, resulting in accumulation of virions close to the cell surface and, as a consequence, in reduced fusion. In agreement with an early block in infection, the inhibition of virus entry could be bypassed by low-pH. RNA replication was not affected. The antiviral effect of ouabain could be relieved by the addition of an Src kinase inhibitor»

In conclusion, in order to verify the possible efficacy of omeprazole and esomeprazole against coronavirus

- The equilibrium of the two forms is determined by the pH of the environment and tested in active (ionized) form in vitro. Unlike an in vitro test, the human body is an open system, a dissipative system. However, the ionized form cannot exceed serum concentrations. The active non-ionized form in the absence of active transport.

But the transformation reaction at the cellular level or under the depletion of the transformation capacity from the inactive form

- As omeprazole can modify or even inhibit the action of the M2 protein at a low level (26), based on a computer simulation, it could be considered to check the inactivation capabilities of omeprazole with protein E of the coronavirus. Protein E is likely to resemble the protein

- In the absence of data clearly showing the effect of omeprazole after being in contact (at a distance of less than 2 to 3 meters) had the effect of coronavirus processes. This immune system a complementary option for itself...

- Personal experience with omeprazole in the context of personal respiratory viral infections since 2007, reminds me of the indication to divide the daily dose into two daily doses (omeprazole already effective for seasonal influenza, acute bacterial rhinitis, allergic rhinitis, asthma)

In the context of the coronavirus pandemic

- share the maximum permissible daily dose of omeprazole in 3 divided doses after being in contact with people at risk of contamination in a 2 to 3 meters

- divide the daily dose of omeprazole into two daily doses

- take the daily dose of omeprazole in two divided doses in a mild condition

- to resume the daily dose of omeprazole in two daily doses when the symptoms of severity diminish.

The effectiveness of esomeprazole may be greater than omeprazole.

Taking into account the aforementioned effects, the use of nasal decongestants with respiratory secretions may become negative (by modifying the pH, the ciliary mobility and the volume) after prolonged use, thus promoting the risk of bacterial pneumonia (29).
The advantages and disadvantages of these drugs depend on the use of cytochrome P 450 (30).

Best regards

Johannes Hambura

1. Long J, Wright F, Molesti E, Temperton N, Bannister W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines. *Emerging Infectious Diseases*. 2016;22(10):1852–1859. doi:10.12688/f1009-1852
2. Dowall SD, Bewley K, Watson RJ, et al. Antiviral Screening of Multiple Compounds against Ebola Virus. *Viruses*. 2016;8(11):277. Published 2016 Oct 7. doi:10.3390/v8110277
3. Sun J, Li X. Pharmacokinetics and pharmacodynamics of antiviral drugs. *Journal of Clinical Pharmacy and Therapeutics*. 2015;40(1):1–10. doi:10.1111/jcpt.12042
4. Spugnini EP, Cifone G, Fais S. Proton pump inhibitors: a new strategy. *J Exp Clin Oncol*. 2010;29(1):14. Published 2010 Mar 8. doi:10.1186/1757-0214-29-14
5. Sasaki T, Yamada M, Yamada H, Inoue D, Yamada M, Kobayashi H, et al. The gastric proton pump inhibitor lansoprazole inhibits the growth of human melanoma cells. *Journal of Pharmaceutical Sciences*. 2005;14:201–210. doi: 10.1016/j.ejphar.2004.12.042.
6. Cecconi P, Loi M, Fais S, et al. Do the common gastric proton pump inhibitors cause influenza-like illness?. *BMC Infect Dis*. 2014;14:297. Published 2014 Jun 2. doi:10.1186/s12879-014-2334-14-297
7. Moormann AEBDP. First antiviral agent in United States 1999 Jun. 14, 2009.
8. Kikuchi S, Naoki Y, Tajiri T, Watanabe N. Proton pump inhibitors for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2018;2018(8):CD013113. Published 2018 Aug 30. doi:10.1002/1469-7580.cd013113
9. Geering K. Nongastric H,K-ATPase: structure and functional properties. *Ann NY Acad Sci*. 2005 Apr;1057:1–12.
10. Matsui MS, Patra ML, Niki Y, Karaman J, et al. The gastric proton pump inhibitor lansoprazole inhibits the growth of human melanoma cells. *Journal of Pharmaceutical Sciences*. 2005;14:201–210. doi:10.1016/j.ejphar.2004.12.042.
11. De Milito A, Cecconi P, Merino ML, Perchi M, Jereb W, Vigna A, Venturi G, Lozungo F, Ferrasi F, Loggini M, Maffei F, Riva F, Rivoltini L, Fais S. pH-dependent proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. *Int J Cancer*. 2009.
12. Lee YY, Jeon HK, Hong JE, et al. Proton pump inhibition enhances the effects of autophagy inhibitors in chemoresistant epithelial ovarian carcinoma. *Oncotarget*. 2015;6(33):35040–35050. doi:10.18632/oncotarget.5319
13. Larsson C, Larsson C, Larsson C, et al. Proton pump inhibitors: a new strategy. *J Exp Clin Oncol*. 2010;29(1):14. Published 2010 Mar 8. doi:10.1186/1757-0214-29-14

P. J. L. ... 2017-2165-1070-1086 ... 10-10074-10000-015-0500-0

30. ... 2017-2165-1070-1086 ... 10-10074-10000-015-0500-0

Let me know

Thanks,

Joslyn

Editor

WTOP News

(202)

period of f
treatm

I cannot
and

Sincerely,

Ching Y. v

Your participation in an invitation to the event or your questions about the event or your invitation.

Best wishes,

Richard

Richard Forster
Executive Director
Trilateral Commission

Thanks,

Jon

Jonathan P. Pook, M.D.

Chief Medical Correspondent

Professor of Medicine

NYU Langone

Twitter @

retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor communication through our internal and external systems. Turner and the Turner marks are trade marks of Turner Broadcasting System, Inc. used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927933), Turner Entertainment Networks International Limited (Company No. 2802512), Turner Broadcasting System Holdings Limited (Company Number 290295), Cable News Network International Limited (Company No. 5001368) are incorporated in England and Wales and are registered in the same register. Their office is at Turner House, 16 Great Marlborough Street, London W1F 7HS.

This information is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please do not distribute, store, retransmit, use or disclose its contents to anyone. You should delete it from your system. If you have received this information in error, please do not distribute, store, retransmit, use or disclose its contents to anyone. You should delete it from your system. If you have received this information in error, please do not distribute, store, retransmit, use or disclose its contents to anyone. You should delete it from your system.

Turner and the Turner marks are trademarks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trademarks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company No. 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trademarks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and

delete it from your system.

contents to anyone. It is

internal and external networks. Turner and the Turner marks are trade marks of Turner

System Inc. and are used under license.

Turner Bro

International Limited (Company No. 2803517), Turner

(Company Number 2802926) and Cable News International Limited

incorporated in the United Kingdom

Marlborough Street, London W1F 7HS.

